LFCR
Price
$5.17
Change
-$0.22 (-4.08%)
Updated
Jun 26 closing price
Capitalization
193.92M
34 days until earnings call
Intraday BUY SELL Signals
PAHC
Price
$31.69
Change
-$0.14 (-0.44%)
Updated
Jun 26 closing price
Capitalization
1.29B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LFCR vs PAHC

LFCR vs PAHC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LFCR vs. PAHC commentary
Jun 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFCR is a Hold and PAHC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2026
Stock price -- (LFCR: $5.16 vs. PAHC: $31.69)
Brand notoriety: LFCR and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LFCR: 405% vs. PAHC: 138%
Market capitalization -- LFCR: $193.92M vs. PAHC: $1.29B
LFCR [@Pharmaceuticals: Generic] is valued at $193.92M. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.29B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LFCR’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 2 green FA rating(s).

  • LFCR’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 2 green, 3 red.
According to our system of comparison, PAHC is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LFCR’s TA Score shows that 5 TA indicator(s) are bullish while PAHC’s TA Score has 6 bullish TA indicator(s).

  • LFCR’s TA Score: 5 bullish, 5 bearish.
  • PAHC’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than LFCR.

Price Growth

LFCR (@Pharmaceuticals: Generic) experienced а -6.95% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was -0.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.11%. For the same industry, the average monthly price growth was +1.35%, and the average quarterly price growth was +10.85%.

Reported Earning Dates

LFCR is expected to report earnings on Jul 31, 2026.

PAHC is expected to report earnings on Sep 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.11% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PAHC($1.29B) has a higher market cap than LFCR($194M). LFCR has higher P/E ratio than PAHC: LFCR (51.23) vs PAHC (13.32). PAHC YTD gains are higher at: -14.622 vs. LFCR (-36.980). PAHC has higher annual earnings (EBITDA): 222M vs. LFCR (-8.81M). PAHC has more cash in the bank: 77.5M vs. LFCR (20.8M). LFCR has less debt than PAHC: LFCR (149M) vs PAHC (787M). PAHC has higher revenues than LFCR: PAHC (1.5B) vs LFCR (129M).
LFCRPAHCLFCR / PAHC
Capitalization194M1.29B15%
EBITDA-8.81M222M-4%
Gain YTD-36.980-14.622253%
P/E Ratio51.2313.32385%
Revenue129M1.5B9%
Total Cash20.8M77.5M27%
Total Debt149M787M19%
FUNDAMENTALS RATINGS
LFCR vs PAHC: Fundamental Ratings
LFCR
PAHC
OUTLOOK RATING
1..100
718
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
10033
PRICE GROWTH RATING
1..100
4963
P/E GROWTH RATING
1..100
695
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (13) in the Pharmaceuticals Major industry is significantly better than the same rating for LFCR (89) in the Industrial Specialties industry. This means that PAHC’s stock grew significantly faster than LFCR’s over the last 12 months.

PAHC's Profit vs Risk Rating (84) in the Pharmaceuticals Major industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that PAHC’s stock grew similarly to LFCR’s over the last 12 months.

PAHC's SMR Rating (33) in the Pharmaceuticals Major industry is significantly better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that PAHC’s stock grew significantly faster than LFCR’s over the last 12 months.

LFCR's Price Growth Rating (49) in the Industrial Specialties industry is in the same range as PAHC (63) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to PAHC’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is significantly better than the same rating for PAHC (95) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LFCRPAHC
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 5 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
LFCR
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTINX13.41N/A
N/A
Fidelity Advisor Asset Manager 30% I
LGOFX34.35N/A
N/A
Lord Abbett Growth Opportunities F
JFIFX13.94N/A
N/A
JHancock Financial Industries I
UANQX70.16N/A
N/A
Victory Nasdaq 100 Index Class A
WCMWX27.86N/A
N/A
WCM Focused Emerging Mkts Ex Chn Inst

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
-4.36%
SHPH - LFCR
31%
Poorly correlated
+5.29%
HLN - LFCR
28%
Poorly correlated
-0.32%
COLL - LFCR
28%
Poorly correlated
+5.02%
PAHC - LFCR
27%
Poorly correlated
-0.44%
TLRY - LFCR
27%
Poorly correlated
+4.37%
More